AREXVY FAQs

Expand all

Collapse all

  • down-arrow What is AREXVY?

    AREXVY is a vaccine that helps to protect adults 60 years of age and older from lower lung disease caused by respiratory syncytial virus (RSV).

  • down-arrow Who can get AREXVY?

    Adults 60 years of age and older may be eligible for the AREXVY vaccine. Talk to your healthcare provider to determine if AREXVY is right for you.

  • down-arrow How is AREXVY given?

    AREXVY is given as a single injection into a muscle (usually in the upper arm).

  • down-arrow What are the most common side effects of AREXVY?

    Very common adverse events (≥10% of doses) reported in clinical trials were:

    • pain at the injection site
    • tiredness
    • headache
    • muscle pain (myalgia) and joint pain (arthralgia).

    Most side effects are mild or moderate and do not last long (usually 1 to 2 days). Please speak to your doctor, pharmacist, or nurse should you have any questions about side effects.

RSV FAQs

Expand all

Collapse all

  • down-arrow What is respiratory syncytial virus (RSV)?

    RSV is a common and highly contagious respiratory virus, causing infections of the lungs and breathing passages.

  • down-arrow Who is at risk?

    RSV can infect people of any age. It usually causes mild, cold-like symptoms but can also cause more serious respiratory illness, as well as make some illnesses and conditions worse in older adults.

  • down-arrow When is RSV season?

    RSV infection can happen at any time of the year, though it does follow a seasonal pattern. In Canada, the RSV season typically starts in late fall and lasts until early spring

Virus icon

WHAT IS RSV?

RSV is a common and contagious respiratory virus that affects the lungs and respiratory airways.

ABOUT RSV
Needle icon

WHAT IS AREXVY?

AREXVY is a single-dose vaccine that helps to protect adults 60 years and older from RSV disease.

WHY AREXVY?

AREXVY is a vaccine that helps to protect adults 60 years of age and older from lower lung disease caused by respiratory syncytial virus (RSV). 100% protection cannot be guaranteed. AREXVY is not indicated for the treatment of RSV and does not prevent or reduce the risk of complications. AREXVY should not be used if you are allergic to any ingredient in the vaccine. Adverse events may occur. Very common adverse events (≥10% of doses) reported in clinical trials were pain at the injection site, tiredness, headache, muscle pain (myalgia), and joint pain (arthralgia). Ask your healthcare professional if AREXVY is right for you. Full product information can be found at gsk.ca/arexvy/en. To report an adverse event, please call 1-800-387-7374.